Reuters: Lilly's Mounjaro Leads To More And Faster Weight Loss Than Novo Obesity Drug, Data Analysis Finds Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's popular rival weight loss drug, according to an analysis of health records and other data. Within one year of starting treatment, 42.3% of those taking tirzepatide - the active ingredient in Mounjaro and Zepbound - had lost at least 15% of their weight, compared with 19.3% among patients taking semaglutide - the main ingredient in Wegovy and Ozempic, the study published on medRxiv in advance of peer review found. (Lapid, 11/27) In related news about menopause treatments — The New York Times: A New Match For Menopausal Weight Gain: Ozempic Kymberly Smith had had enough. It was February 2020, and she was grieving the sudden death of her husband when Covid lockdowns began. She was alone, without any access to her support network, and she was "in the throes of menopause."